Commercial strength
Customer quality, deployment depth, revenue signals, partnership momentum, and evidence of repeatable demand.
Portfolio evaluation
Digital Health Portfolio Evaluation & Risk
Compare ventures and partnerships consistently, surface material risk, and decide where to support, monitor, scale, or exit.
The decision context
Portfolio decisions weaken when every company is assessed differently
Digital health portfolios combine companies at different stages, in different categories, and with very different evidence requirements. Funding alone is a poor proxy for quality, while a single score can hide the precise risk that will prevent adoption or value creation.
Galen Growth evaluates portfolios through a consistent multi-dimensional framework and stratifies risk according to the purpose of the investment, partnership, or programme.
What Galen Growth evaluates
Evidence organised around the decision
Clinical and regulatory position
Clinical evidence, regulatory progress, safety, claims, and suitability for the intended healthcare context.
Organisational resilience
Leadership, operating maturity, capital position, execution capability, and dependence on key people or partners.
Strategic fit and concentration
Alignment with portfolio objectives, duplication, category exposure, dependencies, and correlated sources of risk.
HealthTech Alpha evidence
Risk viewed across evidence, execution, and adoption
HealthTech Alpha combines venture profiles with proprietary maturity measures and underlying records for funding, partnerships, clinical evidence, regulation, team, and market activity. The result is a traceable view of why a company appears strong or exposed, not a black-box ranking.
- Comparable venture profiles
- Commercial and partnership signals
- Clinical and regulatory evidence
- Portfolio-level concentration analysis
Methodology
From question to defensible action
- Define portfolio intent
Set the strategic objective, expected outcomes, time horizon, and risk tolerance for the portfolio.
- Create the evidence model
Weight the commercial, clinical, regulatory, organisational, and strategic dimensions that matter to the decision.
- Evaluate and stratify
Assess each company consistently, document evidence gaps, and group the portfolio by action and risk.
- Set monitoring actions
Define support priorities, review triggers, remediation needs, and criteria for further commitment or exit.
Related case studies
How Galen Growth has supported these decisions
Real World Evidence in China
As part of a full franchise strategy review, a leading pharmaceutical company was looking to evaluate its global portfolio of existing partnerships with Digital Health ventures to confirm fitness for purpose
Competitive analysis in genomics for a reinsurance company
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target.
Key therapeutic area Digital Health portfolio evaluation
As part of a full franchise strategy review, a leading pharmaceutical company was looking to evaluate its global portfolio of existing partnerships with Digital Health ventures to confirm fitness for purpose
Related research
Evidence behind the market
AnalysisDigital Health Funding 2026: Ventures with Strong Clinical Evidence Raise 3.5x More→AnalysisThe Galen Growth HealthTech 250, one year on: separating signal from noise in digital health ventures→AnalysisDigital Health Exits in 2026: M&A Dominance, Longer Hold Periods, and Strategic Consolidation→
Sectors
Designed for healthcare decisions
- Venture capital
- Corporate venture capital
- Biopharma
- Medical device
- Insurance
- Innovation portfolios
FAQ
Common questions
What is digital health portfolio evaluation?
It is the consistent assessment of companies or partnerships across commercial, clinical, regulatory, organisational, and strategic dimensions to support portfolio decisions.
How is portfolio risk stratified?
Risk is grouped by the evidence and execution factors most likely to affect the portfolio objective, with transparent criteria for action rather than a single unexplained score.
Can this be used for partnership portfolios as well as investments?
Yes. The framework can be adapted to pilots, vendors, strategic partnerships, corporate venture investments, or mixed innovation portfolios.
Related capabilities
Explore other decision areas
Your decision context
Bring us the question that needs a defensible answer.
We will help define the evidence, scope, and practical route from analysis to action.